# US 2019/0317100 A1 · Ly75 as cancer therapeutic and diagnostic target

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0317100 A1
- Document ID: US20190317100A1
- Status: Published application
- Kind: A1
- Application number: 16/392,796
- Filed: 2019-04-24
- Published: 2019-10-17
- Earliest claimed: 2012-11-07
- Assignees: Oxford Biotherapeutics Ltd
- Applicants: Oxford Biotherapeutics Ltd.
- Inventors: James E. Ackroyd
- Web page: https://patentgrep.com/patent/US20190317100A1

## CPC

- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6809: {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
- A61K 47/6817: {Toxins}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- C07K 16/30: from tumour cells
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/77: Internalization into the cell
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/10: involving cells
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as lymphoma, myeloma, leukemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer, for monitoring the effectiveness of cancer, such as lymphoma, myeloma, leukemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer treatment, and for drug development.

## Claims

### Claim 1

A method for the treatment of a cancer selected from the group consisting of lymphoma, myeloma, leukaemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer wherein LY75 is expressed in said cancer, which comprises administering to a subject in need thereof a therapeutically effective amount of an affinity reagent which binds to LY75, wherein said affinity reagent is conjugated to a therapeutic moiety.

### Claim 2 (depends on 1)

The A method according to claim 1, wherein lymphoma is selected from the group consisting of non-Hodgkin's lymphoma, Diffuse Large B-Cell Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT), T-Cell/Histiocyte-Rich B-Cell Lymphoma, Burkitt Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma and Angiolmmunoblastic T-Cell Lymphoma.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the affinity reagent binds specifically to LY75.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the affinity reagent is an antibody, a monoclonal antibody, a chimeric antibody, a human antibody, a humanized antibody, a single chain antibody, a defucosylated antibody or a bispecific antibody, or a functional fragment thereof or antigen-binding portion thereof, or an antibody mimetic.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 4)

The method according to claim 4, wherein
a) the functional antibody fragment is a UniBody, a domain antibody or a Nanobody; or
b) the antibody mimetic is an Affibody, a DARPin, an Anticalin, an Avimer, a Versabody or a Duocalin.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method according to claim 1, wherein the therapeutic moiety is a cytotoxic moiety or a radioactive isotope.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the cytotoxic moiety is selected from the group consisting of duocarmycins, calicheamicins, maytansines and auristatins, or derivatives thereof.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the affinity reagent is an antibody drug conjugate.

### Claim at position 11

-16. (canceled)

### Claim 17

A method of detecting, diagnosing and/or screening for or monitoring the progression of a cancer selected from the group consisting of lymphoma, myeloma, leukaemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer wherein LY75 is expressed in said cancer, or of monitoring the effect of a cancer drug or therapy directed to said cancer, in a subject which comprises:
a) detecting the presence or level of LY75, or one or more fragments thereof, or the presence or level of nucleic acid encoding LY75, or which comprises detecting a change in the level of either thereof in said subject; or
b) detecting the presence or level of antibodies capable of immunospecific binding to LY75, or one or more fragments thereof.

### Claim 18 (depends on 17)

The method according to claim 17 which comprises detecting the presence of LY75, or one or more fragments thereof, or the presence of nucleic acid encoding LY75, in which either (a) the presence of an elevated level of LY75, or said one or more fragments thereof, or an elevated level of nucleic acid encoding LY75 in the subject as compared with the level in a healthy subject, or (b) the presence of a detectable level of LY75, or said one or more fragments thereof, or a detectable level of nucleic acid encoding LY75 in the subject as compared with a corresponding undetectable level in a healthy subject is indicative of the presence of said cancer in said subject.

### Claim 19

(canceled)

### Claim 20 (depends on 17)

The method according to claim 17 wherein the presence of LY75, or one or more fragments thereof, or the presence of nucleic acid encoding LY75, or the presence or level of antibodies capable of immunospecific binding to LY75, or one or more fragments thereof, is detected by analysis of a biological sample obtained from the subject.

### Claim 21 (depends on 17)

The method according to claim 17 wherein the presence of LY75, or one or more fragments thereof, is detected using an affinity reagent which binds to LY75.

### Claim 22 (depends on 21)

The method according to claim 21 wherein the affinity reagent is an antibody, a monoclonal antibody, a chimeric antibody, a human antibody, a humanized antibody, a single chain antibody, a defucosylated antibody or a bispecific antibody, or a functional fragment thereof or antigen-binding portion thereof, or an antibody mimetic.

### Claim 23 (depends on 21, 22)

The method according to claim 21 or 22 wherein the affinity reagent contains or is conjugated to a detectable label.

### Claim 24 (depends on 1)

The method according to claim 1 wherein the subject is a human.

### Claim 25

A method for identifying an agent for the treatment or prophylaxis of a cancer selected from the group consisting of lymphoma, myeloma, leukaemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer wherein LY75 is expressed in said cancer, wherein the method comprises (a) contacting LY75, or one or more fragments thereof, with a candidate agent; and (b) determining whether the agent binds to LY75, or said one or more fragments thereof.

### Claim 26 (depends on 25)

The method according to claim 25 further comprising the step of testing the ability of an agent which binds to LY75, or one or more fragments thereof, to:
a) inhibit said cancer; and/or
b) to modulate a physiological function of LY75, inhibit ligand binding to LY75 and/or inhibit a signal transduction pathway mediated by LY75.

### Claim at position 22

27-28. (canceled)

### Claim 29 (depends on 1)

The method according to claim 1, wherein the cancer is multiple myeloma or Triple-Negative breast cancer.
